

产品名称: **Alfuzosin hydrochloride**  
 产品别名: 盐酸阿夫唑嗪; **SL 77499-10**

生物活性:																					
Description	Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). Target: α1 adrenergic receptor Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia. Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component to their obstruction. In addition, alfuzosin offers an alternative to prostatectomy (the current 'gold standard') in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery.																				
	<p><b>In Vitro:</b></p> <p><b>H<sub>2</sub>O : 50 mg/mL (117.40 mM; Need ultrasonic)</b></p> <p><b>DMSO : 12.5 mg/mL (29.35 mM; Need ultrasonic)</b></p> <table><tr><td rowspan="4">Preparing Stock Solutions</td><td><div>Solvent / Mass / Concentration</div></td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>2.3479 mL</td><td>11.7396 mL</td><td>23.4791 mL</td></tr><tr><td>5 mM</td><td>0.4696 mL</td><td>2.3479 mL</td><td>4.6958 mL</td></tr><tr><td>10 mM</td><td>0.2348 mL</td><td>1.1740 mL</td><td>2.3479 mL</td></tr></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限: -80℃, 6 months; -20℃, 1 month. -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 0.83 mg/mL (1.95 mM); Clear solution</p> <p>此方案可获得 ≥ 0.83 mg/mL (1.95 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀; 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p>					Preparing Stock Solutions	<div>Solvent / Mass / Concentration</div>	1 mg	5 mg	10 mg	1 mM	2.3479 mL	11.7396 mL	23.4791 mL	5 mM	0.4696 mL	2.3479 mL	4.6958 mL	10 mM	0.2348 mL	1.1740 mL
Preparing Stock Solutions	<div>Solvent / Mass / Concentration</div>	1 mg	5 mg	10 mg																	
	1 mM	2.3479 mL	11.7396 mL	23.4791 mL																	
	5 mM	0.4696 mL	2.3479 mL	4.6958 mL																	
	10 mM	0.2348 mL	1.1740 mL	2.3479 mL																	
Solvent&Solubility																					
References	<p>[1]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. <u>Drugs</u>. 1993 Mar;45(3):410-29.</p>																				